Cargando…
A Novel, Orally Delivered Antibody Therapy and Its Potential to Prevent Clostridioides difficile Infection in Pre-clinical Models
Clostridioides difficile infection (CDI) is a toxin-mediated infection in the gut and a major burden on healthcare facilities worldwide. We rationalized that it would be beneficial to design an antibody therapy that is delivered to, and is active at the site of toxin production, rather than neutrali...
Autores principales: | Roberts, April K., Harris, Hannah C., Smith, Michael, Giles, Joanna, Polak, Oktawia, Buckley, Anthony M., Clark, Emma, Ewin, Duncan, Moura, Ines B., Spitall, William, Shone, Clifford C., Wilcox, Mark, Chilton, Caroline, Donev, Rossen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537341/ https://www.ncbi.nlm.nih.gov/pubmed/33072047 http://dx.doi.org/10.3389/fmicb.2020.578903 |
Ejemplares similares
-
The use of first-generation cephalosporin antibiotics, cefalexin and cefradine, is not associated with induction of simulated Clostridioides difficile infection
por: Buckley, Anthony M, et al.
Publicado: (2021) -
In vitro models to study Clostridioides difficile infection: current systems and future advances
por: Ewin, Duncan, et al.
Publicado: (2023) -
Biofilms harbour Clostridioides difficile, serving as a reservoir for recurrent infection
por: Normington, Charmaine, et al.
Publicado: (2021) -
Omadacycline Gut Microbiome Exposure Does Not Induce Clostridium difficile Proliferation or Toxin Production in a Model That Simulates the Proximal, Medial, and Distal Human Colon
por: Moura, Ines B., et al.
Publicado: (2019) -
The structure of the S-layer of Clostridium difficile
por: Bradshaw, William J., et al.
Publicado: (2017)